Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Eficácia do Sistema Modular de Estimulação EMPOWER™ e CDI Subcutâneo EMBLEM™ para Comunicar Estimulação Antitaquicardia (MODULAR ATP)

9 de novembro de 2026 atualizado por: Boston Scientific Corporation

The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Therapy System.

Visão geral do estudo

Status

Ativo, não recrutando

Intervenção / Tratamento

Descrição detalhada

The MODULAR ATP Clinical Study will enroll subjects with a standard Implantable Cardioverter Defibrillator (ICD) indication applying international practice guidelines, as well as those who already have an implanted S-ICD System and satisfy the inclusion criteria for this study, while not meeting any exclusion criteria. Subjects will be followed for at least 6 months following mCRM Therapy System implantation.

Tipo de estudo

Intervencional

Inscrição (Real)

297

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Québec, Canadá
        • Institut Universitaire de Cardilogie et Pnuemologie de Quebec (IUCPQ)
    • Quebec
      • Montreal, Quebec, Canadá, H1T 1C8
        • Institut de Cardiologie de Quebec (Montreal Heart)
      • Barcelona, Espanha, 08036
        • Hospital Clinic of Barcelona
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85006
        • Banner University Medical Center Phoenix
      • Scottsdale, Arizona, Estados Unidos, 84258
        • Scottsdale Healthcare - Shea
    • Arkansas
      • Jonesboro, Arkansas, Estados Unidos, 72401
        • Arrhythmia Research Group
    • Florida
      • Orlando, Florida, Estados Unidos, 32803
        • AdventHealth Orlando
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30308
        • Emory University Hospital
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40503
        • Baptist Health Lexington
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic
    • New Jersey
      • Camden, New Jersey, Estados Unidos, 08103
        • Cooper Hospital - University Medical Center
    • New York
      • Manhasset, New York, Estados Unidos, 11030
        • Northwell University Hospital
      • New York, New York, Estados Unidos, 10029
        • Mount Sinai Medical Center
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic
      • Columbus, Ohio, Estados Unidos, 43210
        • Ohio State University Medical Center
      • Columbus, Ohio, Estados Unidos, 43214
        • Ohio Health Research Institute
    • Pennsylvania
      • Hershey, Pennsylvania, Estados Unidos, 17033
        • Penn State Health Milton S. Hershey Medical Center
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Hospital of the University of Pennsylvania
    • Tennessee
      • Chattanooga, Tennessee, Estados Unidos, 37403
        • Erlanger Medical Center
    • Virginia
      • Norfolk, Virginia, Estados Unidos, 23507
        • Sentara Norfolk General
    • Washington
      • Seattle, Washington, Estados Unidos, 98195
        • University of Washington Medical Center
      • Grenoble, França
        • CHU Grenoble - Hospital Michallon
      • Lille, França, 59000
        • CHRU de Lille
      • Nantes, França
        • CHU de Nantes-Hopital Laennec
      • Paris, França
        • Hospital European Georges-Pompidou
      • Amsterdam, Holanda
        • Amsterdam University Medical Center
      • Nieuwegein, Holanda
        • St. Antonius Ziekenhuis
      • Rotterdam, Holanda, 3015 CE
        • Erasmus MC University Medical Center
      • Brescia, Itália
        • Spedali Civil di Brescia
      • Cotignola, Itália
        • Maria Cecilia Hospital SPA
      • Naples, Itália, 80131
        • AZ Osp Monaldi
      • Pisa, Itália, 56126
        • Azienda Ospedaliero Universitaria Pisana
      • Leeds, Reino Unido, LS1 EX
        • The General Infirmary
      • Liverpool, Reino Unido, L14 3PE
        • Liverpool Heart and Chest Hospital
      • Manchester, Reino Unido, M13 9WL
        • Manchester Heart Center
      • Southampton, Reino Unido
        • Southampton University Hospital
      • Prague, Tcheca
        • Na Homolce Hospital
      • Linz, Áustria
        • Kepler Universitaetsklinikum

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Patient who meets Class I, IIa, or IIb guideline ICD indications[i],[ii], or who has an existing TV-ICD[iii] or S-ICD[iv]

  • Patient who is deemed to be at risk for MVT based on at least ONE of the following:

    • History of Non-Sustained MVT with LVEF ≤ 50%
    • History of sustained VT/VF (secondary prevention) with LVEF ≤ 50% or significant cardiac scar*
    • History of syncope deemed to be arrhythmic in origin
    • History of ischemic cardiomyopathy with LVEF ≤35%
    • History of non-ischemic cardiomyopathy with LVEF ≤35% and significant scar*
  • Patient who is willing and capable of providing informed consent (which is not to include the use of a legally authorized representative (LAR) for documentation of informed consent) and participating in all testing associated with this investigation at an approved study site and at the intervals defined by this protocol

  • Patient who is age 18 years or above, or of legal age to give informed consent specific to state and national law

Exclusion Criteria:

  • Patient with an ongoing complication due to Cardiac Implantable Electronic Device (CIED) infection or CIED explant

  • Transvenous lead remnants within the heart from a previously implanted CIED (Note: transvenous lead remnants outside the heart (e.g., in the SVC) are allowed)

  • Patient with a known LA thrombus

  • Patient with a ventricular arrhythmia due to a reversible cause

  • Patient indicated for implantation of a dual chamber pacemaker or cardiac resynchronization therapy (CRT)

  • Patient with another implanted medical device that could interfere with implant of the leadless pacemaker, such as an implanted inferior vena cava filter or mechanical tricuspid heart valve

  • Patient requires rate-responsive pacing therapy

  • Patient is entirely pacemaker-dependent (defined as escape rhythm ≤ 30 bpm)

  • Patient with Acute Coronary Syndrome (i.e. Acute Myocardial Infarction, Unstable Angina) within 40 days

  • Inability to access femoral vein with a 21-French or larger inner diameter introducer sheath due to known anatomy condition, recent surgery, and/ or other relevant condition

  • Patient who has an active implanted electronic medical device intended for chronic use concomitantly with the study system, such as a left ventricular assist device (LVAD). Note that a temporary pacing wire is allowed.

  • Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)

  • Patient with a known cardiovascular anatomy that precludes implant in the right ventricle

  • Patient with a known allergy to any system components

  • Patient with a known or suspected intolerance to S-ICD conversion testing, based on physician discretion

  • Patient is not likely to have meaningful survival** for at least 12 months (documented or per investigator's discretion)

  • Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/ registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.

  • Patient who is a woman of childbearing potential who is known to be pregnant at the time of study enrollment (method of assessment upon investigator's discretion)

    [i]Al-Khatib, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. (2018); 138:e272-e391.

[ii] 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). European Heart Journal (2015) 36, 2793-2867.

[iii] TV-ICD system is expected to be fully explanted during or prior to full Coordinated System implant

[iv] Potential subjects with a Model 1010 S-ICD Pulse Generator are only eligible for MODULAR ATP if they are getting upgraded to Model A209, A219 or future BSC S-ICD Pulse Generator; Patients with an existing S-ICD PG subject to the electrical overstress field action are only eligible for MODULAR ATP if they are getting a new BSC Model A209 or A219, or future BSC S-ICD Pulse Generator

*Significant cardiac scar is defined as a scar involving at least one ventricular myocardial segment (i.e., basal infero-septum) as identified in the official findings of a cMRI, or nuclear viability study, or echo report by the interpreting radiologist/ cardiologist who is not affiliated with the study

**meaningful survival means that a patient has a reasonable quality of life and functional status

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: MODULAR ATP Study Participants

All subjects that signed the informed consent were included.

Patients consented to receive the mCRM Therapy System which consists of the EMPOWER Leadless Pacemaker and an EMBLEM S-ICD upgraded with investigational firmware.

Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.

Outros nomes:
  • Comunicação de S-ICD para marcapasso cardíaco sem chumbo (LCP)

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Safety Endpoint 1: Percentage of Subjects Without Major EMPOWER MPS System- or Procedure-Related Complications Through 6 Months
Prazo: Implant through 6 Months Post-Implant

Major EMPOWER MPS System- and Procedure-related Complication-Free Rate Subjects will be assessed for safety issues related to the procedure or system through 6 months post implant

Implant through 6 Months Post-Implant
Safety Endpoint 2: Percentage of Subjects Without Major EMPOWER MPS System- or Procedure-Related Complications Through 12 Months
Prazo: Implant through 12 Months Post-Implant

Major EMPOWER MPS System- and Procedure-related Complication-free Rate

Subjects will be assessed for safety issues related to the procedure or system through 12 months post implant

Implant through 12 Months Post-Implant
Primary Effectiveness Endpoint 1: Percentage of Body Postures With Communication Success Between the S-ICD and EMPOWER PG
Prazo: At the 6 Month Follow-up

Communication Success between the S-ICD and EMPOWER PG

Data from subjects will be assessed for effectiveness of communication between S-ICD and the EMPOWER PG by evaluating if a paced beat is present during communication testing in four postures: upright, supine, and right and left side.

At the 6 Month Follow-up
Primary Effectiveness Endpoint 2: Percentage of Subjects Classified as a Pacing Capture Threshold (PCT) Responder
Prazo: At the 6 Month Follow-up

Proportion of Subjects with Adequate Pacing Capture Threshold

Effectiveness will be confirmed by evaluating the percentage of subjects considered to be a PCT Responder, defined as a subject with a PCT measurement of ≤ 2.0 V @ 0.4 ms pulse width

At the 6 Month Follow-up

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Secondary Effectiveness Endpoint: Subject-specific Slope of EMPOWER PG Sensor-Indicated Rate to the Subject's Workload on Treadmill Test
Prazo: At the 3 Month Visit

Metabolic-Chronotropic Relation Slope (MCR Slope) from the Kay-Wilkoff Model

Using the Kay-Wilkoff model, data will be assessed to evaluate the proportionality of the EMPOWER PG's sensor-indicated rate to the subject's workload during the treadmill test

At the 3 Month Visit
Secondary Safety Endpoint
Prazo: Implant through 2 years post-implant

All-Cause Survival; data not reported as it is still being collected

Implant through 2 years post-implant

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Reinoud Knops, MD, PhD, Amsterdam University Medical Centre
  • Investigador principal: Lluis Mont, MD, PhD, Hospital Clinic, University of Barcelona
  • Investigador principal: Vivek Reddy, MD, The Mount Sinai Hospital
  • Investigador principal: Michael Lloyd, MD, Emory University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de julho de 2021

Conclusão Primária (Real)

6 de maio de 2024

Conclusão do estudo (Estimado)

31 de dezembro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

8 de março de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de março de 2021

Primeira postagem (Real)

15 de março de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

There is no plan to share IPD with other researchers in this study.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever